- Evaluate how histology, PD-L1 expression level, and disease burden influence the treatment selection in squamous and non-squamous NSCLC.
- Differentiate between PD-L1 inhibitors based on trial populations, design, and real-world applicability to support evidence-based decision-making.
- Apply best practices for managing immune-related adverse events, updating order sets, and integrating liquid biopsy results to guide patient-specific immunotherapy decisions.
PD-L1 Inhibitors in NSCLC: Precision, Personalization, and Practice Impact
December 2, 2025 | 5:30 PM-8:30 PM
The Smith, 400 N Clark St, Chicago, IL 60654
Our Mission
Pharmacy Times® Clinical Forum events are roundtable discussions in specific therapeutic areas led by specialized practitioners and designed to share their real-world experiences and best practices. Pharmacy Times recaps discussions and creates articles and content to be featured in Pharmacy Times print publications and on pharmacytimes.com.
With the goal of advancing clinical outcomes and improving patient care, Pharmacy Times offers the latest news and insights for the pharmacy professional, along with solutions that impact the everyday practice of pharmacy. Our family of print publications, digital resources, and live events such as Clinical Forum discussions offer countless opportunities for expanding and sharing knowledge among pharmacy professionals.
Meeting Objectives:
Attendees benefit by:
Engaging with peers on scientific advancements, innovative treatment protocols, and effective patient management approaches.
Discovering implementation strategies from leading institutions and centers of excellence that have transformed patient outcomes.
Building valuable professional relationships with fellow specialists that extend beyond the event.
Attendee Testimonials
COUNTDOWN TO CLINICAL FORUM
2025 Copyright Pharmacy Times® Pharmacy and Healthcare Communications, LLC All Rights Reserved.
